Sinphar Pharmaceutical Co. Ltd. · TWSE:1734
Sinphar Pharmaceutical — 2023 Sinphar Pharmaceutical Investor Conference
33 slides from Sinphar Pharmaceutical's conference presentation, Dec 13, 2023
Slide 1: Sinphar：1734 SynCore：4192
Sinphar：1734 SynCore：4192 1
Slide 2: Disclaimer
Disclaimer 本簡報是建立於本公司從各項來源所取得之資訊。有些 訊可能受未來不確定性因素影響，致使與原先本公司對 於未來前景的說明迥異。未來若有變更或調整時，請以 公開資訊觀測站公告資訊為依據。 所涉產業為法規高度規範與高度專業領域，提醒投資人 須審慎投資。 This presentation is based on the information obtained from various sources which the Company believes to be reliable. But at some point in the future, there ar
Slide 3: Contents
Contents 1. Outlook 2. Operations Development 3. Financial Reports 4. ESG 5. Social Responsibility 3
Slide 4: From Taiwan to the World
From Taiwan to the World 2000 Sinphar TPEx-listed 2002 Sinphar TWSE-listed 2014 SynCoreBio TPEx-listed 1977 2002 2012 Established Sinphar Invested in Sinphar TianLi & Merged ZuniMed Ilan, Taiwan He-Tian Tianli Biotech Generic drugs, functional food, Hangzhou (CN), Xinjiang(CN) Nantou, Taiwan cosmeti
Slide 5: Major Developments
Major Developments Diverse Development of Generic Drugs Value-added New Drugs R&D Comprehensive Plans for Natural Plant Extracts 5
Slide 6: Integration
Stride Ahead According to TFDA as of 12/1 and DCB data: Integration 1. API manufacturer:29 Supplier 2. Western medicine Exporting to over 10 manufacturer:144 countries/regions and increasing. 3. Pharmaceutical/medicinal related companies: over 100 4. Medical device companies: over 10,000 Internation
Slide 7: Integration of Resources
Integration of Resources Sinphar & SynCore • Joint R & D • Improvement in Oncology manufacturing (Example: freeze-drying Dosages process) Sinphar & TianLi Natural Medical • Mutual benefit in Herbal Devices R&D achievement Extraction • Strategic cooperation for Sinphar & ZuniMed patented products ISO
Slide 8: Management Philosophy
Management Philosophy Respecting Life and Health Average salary per employee (in NTD) Lanyang Mazu Cultural Celebration Sponsors Sinphar Yilan Marathon 600,000 550,000 Sponsors Taiwan Alzheimer’s Disease Collaborates with local government to 500,000 Association promote chiang gu Jan-Sep 2021 Jan-Sep
Slide 9: Comprehensive Product Line for All Ages
Comprehensive Product Line for All Ages Dermatology Ophthalmology Pediatrics Oncology Otolaryngology Orthopedics Obstetrics & General Surgery Plastic Surgery Gynecology Metabolism Dental Gastroenterology Urology General Medicine Psychiatry New Product Released in 2023: 3 New Product Released in 2023
Slide 10: Health Around the Corner
° Aim bs SINPHAR GROUP Health Around the Corner wee a — i a agane 28 = a 10} OF 4 wt Wish. seaaREED <g , = - -_ . 1:7 7 ML | =| ES Giese <a AH Life + Health + Technology
Slide 11: Post Pandemic Care
© Aye Bo ee iat roe Post Pandemic Care Rae COVID-19S NER RE RUREE A Ac H IRAN TEM ? o> fle BE RR ie y (ESNDR HPN GEER) FUR ER IB + BB» UHR é val HbR X 7S EAR RETHECOORA | A cee GH SRB feete ARH {a O ; 1c See ‘be | y a 7 \ y SS omin . tip - + FH Life > Health + Technology SE ttt~—~O—CS
Slide 12: International Award Winning Product
International Award Winning Product 12
Slide 13: Potent Plus Soft Capsules
| Sea eee SINPHAR GROUP AG BA Vitamin B1 etc si aad Heart Health aa RTBU S BAMA es jy Fie U2) 3 Exclusive Anti-Fatigue Ingredients With Patents Potent Plus Soft Capsules D Gana FBLA BNR MES 1D BE MET AE) Echinacoside QH D-Ribose in a Git565519™ 5 “lity Mode\ Pe a PEI e tun High gn Enero Levels 5 pat
Slide 14: 經107例人體試驗 證實有感提升保護
經107例人體試驗 證實有感提升保護 *文獻發表中 經國際學術發表文獻證實 具調節免疫、緩解過敏體質雙重作用
Slide 15: Health Foods for Aging Society
Health Foods for Aging Society 三高全照護健康食品系列
Slide 16: Sinphar Health Park – Sharing Knowledge with the Public
Sinphar Health Park – Sharing Knowledge with the Public 1. Since the opening of the Park, approximately 80,000 people have come to understand the manufacturing process of pharmaceuticals and food products. An expansion plan is underway to accommodate the expected 60,000 visitors for 2024 2. Located
Slide 17: Production Digitalization
Production Digitalization Production Plan Scheduling Shipping Create Work BI Cockpit Warehouse MRP Order PO Warehouse Receiving ISO/IEC 27001 IQC ISMS QA Warehouse FQC Warehouse Weighing Packaging Picking MM WIP Warehouse MP WIP Warehouse IPQC Cockpit ERP LIMS Production Data APS MES PLC & Equipment
Slide 18: International Markets
International Markets Japan • Product G, launched in 2020, steady Philippines growth • Product L, applied in 2022, expect to Thailand launch in 2024 • Product T, apply in 2024, expect to • Product G, obtained license in 2023 launch in 2026 Vietnam • Product G, obtained license in 2023 • Product G, e
Slide 19: Sustainability
Sustainability Energy Saving Carbon Reducing Average annual saving 7.4% reduction in direct greenhouse gas emissions 2.11% (Based on 2015-2022 verified reporting to 4.6% reduction in sludge the Bureau of Energy, Ministry of Economic Affairs, Conservation Audit removal volume per month Technology Inf
Slide 20: Growth
Growth Therapeutic Drugs • 3 New listings are expected in 2024 • Co-develop and manufacture with Japanese pharmaceutical companies and expand ASEAN market • Agent to Japanese products for domestic market • API in-depth development plan • Establish domestic alliance Functional Supplements • 4 New lis
Slide 21: Cancer Drug Dosage Development
Cancer Drug Dosage Development Target Indication Patient* Product Target Indication Type Method (number of patients/year in Taiwan) Colon Cancer Self-Developed Colon Cancer: 16829/year SCB321 Generic Stomach Cancer (incl. API) Stomach Cancer: 4257/year SCB211 Liver Cancer Generic Import Liver
Slide 22: Pipeline
e e Bi ° Pipeline a aia INNOVATIVE DRUG CLINICAL PHASE | PHASE II PHASE III NDA MARKETED $801 Head & Neck Cancer > $B02 Solid Tumor = : A EndoTAG’ -1 SE <ciobal Pancreatic Cancer (PC) > chi SBOS hina EndoTAG -1 ee ae . Taiwan : Triple Negative Breast Cancer (TNBC) Dermatol E . ° = $803 meee > S Exte
Slide 23: Sinphar Group's New Drug Catalog
Refer to Annual Report from Sinphar and Sinphar Group's New Drug Catalog SynCore for more details Memoregain® SB05 PC SB03 Veregen TLCT Plus Pancreatic Cancer Vascular dementia EGW Second Line Treatment:Clinical trial Phase Ⅲ Launched in 20 Obtained license First Line Treatment: NMPA approved; Phase
Slide 24: Memoregain® TLCT Plus Lipucan®
天然資源（原料/提取物） Memoregain® Lipucan® Protygold ® KAZINAKE ® TLCT Plus 天力速康® 杏补宜 ® 杏补宜 ® 天力再生® 茯苓三萜菁萃物 核桃肽 初榨核桃油 (Poria cocos triterpenoids) (Walnut oligopeptide) (Walnut Oil) 管花肉蓯蓉提取物 (Cistanche tubulosa extract) Organic certification EU Ecocert、USDA Organic、China Organic Food Certification Center 24
Slide 25: RD research achievements
RD research achievements Walnut oil won the ITQI and Monde Selection awards in 2023 Walnut oligopeptide won 4 gold and 1 silver international patent invention awards in 2022 Walnut oligopeptide obtains Nutritional Intelligence_ New Plant Power Award SCI papers The ingredient has been sold to 14 pate
Slide 26: Differentiated Marketing
Differentiated Marketing • Major markets in Taiwan and China as food raw material; Market begin to export in 2021 now sold to 14 countries around the world • Looking for new markets post COVID-19 pandemic • Provide specialized customer support with R&D and Marketing technical advantage and comprehen
Slide 27: Profit/Loss
Profit/Loss NTD in Thousand 3,000,000 2,214,367 2,094,144 2,000,000 1,792,176 1,000,000 213,378 265,321 0 (23,099) Q1~Q3 2021 Q1~Q3 2022 Q1~Q3 2023 (1,000,000) Revenue Net income (loss) Net income (loss) attributable to parent company’s shareholders Sales revenue and net profit showing growing trend
Slide 28: Sales Revenue
NTD in Thousand Sales Revenue 2,500,000 2,214,367 Q1-Q3 2021 Q1-Q3 2022 Q1-Q3 2023 2,094,144 2,000,000 Taiwan 1,470,928 1,695,190 1,905,622 1,792,176 1,500,000 China 127,988 148,683 137,435 USA 54,071 114,723 0 1,000,000 Vietnam 58,096 32,952 54,417 500,000 Indonesia 2,081 19,850 51,869 0 Other 79,0
Slide 29: Ratio
NTD in Thousand Ratio Q1~Q3 2022 Q1~Q3 2023 Debt Ratio (%) 47.0 47.2 Current Ratio (%) 207.7 217.8 Accounts Receivable Turnover 4.43 4.70 Accounts Payable Turnover 6.23 6.94 Inventory Turnover 2.41 2.35 Sinphar SynCore Q3 2023 Q3 2023 Cash and cash equivalents, 995,134 148,176 end of the period Unsp
Slide 30: Corporate Social Responsibility
Corporate Social Responsibility 1. Host health forum, biotechnology camp. Create a platform to facilitate and cultivate the interaction of medical, academic, and biotechnology professionals 2. Continue to be a sponsor for Breast Cancer Foundation, Spinal Cord Injury Foundation, The Diabetes Associat
Slide 31: Corporate Social Responsibility
Corporate Social Responsibility Supports Education and Sports 1. Donate NTD 5 million over 5 years to Kaohsiung Medical University for students in need of financial assistance 2. Sinphar Group and Yilan County Government will jointly organize annual “Sinphar Yilan Marathon” for 3 years with a sponso
Slide 32: ESG Policy
ESG Policy E S G 1. Energy 1. Employee 1. Business Management Benefits Management 2. Emission 2. Stakeholders 2. Risk Management Reduction 3. Value Chain 3. Charity and Management 3. Eco-friendly Education Not just a slogan, we believe that through the above, we can see the efforts and hard work of
Slide 33: “SR RRSS
“SR RRSS SINPHAR GROUP m+ 2 & > HH Life » Health * Technology SS —~—
Sinphar Pharmaceutical — 2023 Sinphar Pharmaceutical Investor Conference on 6ix